Antiatherogenic effects of the antioxidant BO-653 in three different animal models
-
- Osamu Cynshi
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Yoshiki Kawabe
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Tsukasa Suzuki
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Yoshiaki Takashima
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Hiroshi Kaise
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Minako Nakamura
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Yasuhiro Ohba
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Yoshiaki Kato
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Kunio Tamura
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Akira Hayasaka
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Atsuko Higashida
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Hisashi Sakaguchi
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Motohiro Takeya
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Kiyoshi Takahashi
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Kenji Inoue
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Noriko Noguchi
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Etsuo Niki
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
-
- Tatsuhiko Kodama
- Fujigotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka 412, Japan; The Second Department of Biochemistry, Kumamoto University Medical School, 2-2-1 Honjo, Kumamoto 860, Japan; Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan; and Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro, Tokyo 153, Japan
抄録
<jats:p> Antioxidants have been proposed to have antiatherogenic potential by their inhibition of low density lipoprotein (LDL) oxidation. Here, we report an antioxidant, BO-653 (2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di- <jats:italic>tert-</jats:italic> butylbenzofuran), designed to exhibit antioxidative potency comparable to that of α-tocopherol, but yet possess a high degree of lipophilicity comparable to that of probucol. BO-653 exhibits a high affinity for LDL and is well distributed in aortic vessels <jats:italic>in vivo</jats:italic> . In atherosclerosis models of rabbits and mice, BO-653 has been shown to be able to suppress the formation of atherosclerotic lesions without untoward side effects. Specifically, there was no reduction of high density lipoprotein levels. This antioxidant provides additional evidence in support of the oxidized-LDL hypothesis, and itself is a promising candidate antioxidant for clinical use. </jats:p>
収録刊行物
-
- Proceedings of the National Academy of Sciences
-
Proceedings of the National Academy of Sciences 95 (17), 10123-10128, 1998-08-18
Proceedings of the National Academy of Sciences
- Tweet
キーワード
詳細情報
-
- CRID
- 1364233268922471552
-
- NII論文ID
- 30016227418
-
- ISSN
- 10916490
- 00278424
-
- データソース種別
-
- Crossref
- CiNii Articles